Merck and Roche’s immunotherapies are each approved solo for certain bladder cancer patients. But for others, chemo may work better, the FDA warned.
China’s WuXi Biologics is at it again, announcing plans for a third new manufacturing site in less than a month.
Samsung BioLogics is well on its way to becoming the world's largest contract manufacturer.
Celgene's business development chief George Golumbeski left the company in April as Celgene struggles to recover from months of setbacks.
About 35% of shareholders voted against AstraZeneca's executive pay, including the £9.4 million pay package for CEO Pascal Soriot.
Roche's Hemlibra, on its way to treating a much wider population, put up some big data over the weekend that should back its bid at FDA.
Don't dismiss Trump's move to put drug prices in DTC ads. Five senators wrote top execs urging them to do it voluntarily or face congressional action.
Lokelma moved past two rejections to win its nod, and now it's ready to tackle Vifor's hyperkalemia rival Veltassa, approved back in 2015.
UCB is sponsoring an effort to create a clinical care standard for women with inflammatory bowel disease (IBD) before, during and after pregnancy.
The FDA has OK’d the Daewoong manufacturing plant that will make Evolus’ Botox copy but rejected Evolus' drug over its manufacturing design.
The One Show’s return to health and pharma recently resulted in a slew of creative awards, but only one of them went to an actual drugmaker.